Passive Adverse Event Approach Is Key Facet Of US FDA's Right-To-Try Rule
Executive Summary
Sponsors will have little obligation to conduct due diligence of adverse events experienced with right-to-try drug use under a proposed FDA rule, leading critics to once again raise safety concerns with the pathway for accessing experimental medicines. The agency will not help patients or companies determine whether drugs qualify for right-to-try.